Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies

Rashi Minocha, Richard Kefford, Pablo Uribe, Deshan F. Sebaratnam, Pablo Fernández-Peñas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Diffuse melanosis cutis (DMC) is a rare presentation of metastatic melanoma associated with a particularly guarded prognosis. We report a case of a 35-year-old man with BRAFV600E metastatic melanoma treated with dabrafenib (as well as ipilimumab and whole brain radiotherapy), who is alive, 25 months after the onset of his DMC. This is significantly longer than the reported mean survival of 4 months, highlighting the importance of BRAF mutation testing and the promising survival advantage of using targeted therapies compared with conventional chemotherapeutic regimens.

Original languageEnglish
Pages (from-to)128-130
Number of pages3
JournalAustralasian Journal of Dermatology
Volume56
Issue number2
DOIs
Publication statusPublished - 1 May 2015
Externally publishedYes

Fingerprint Dive into the research topics of 'Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies'. Together they form a unique fingerprint.

Cite this